The doctors knew that the patient had HIV so they deliberately chose a donor with two copies of the mutated CCR5 gene. The mutation occurs in about 3 % of Europeans said the researchers. The transplant was successful and there were no significant irregularities the doctors said, aside from the fact, Not only that,tment on the day the patient received the transplant and no no. Not only did the leukemia disappeared, but so has the HIV, it seems. But even if it turns out that the patient was cured of donated bone marrow, neither the doctors nor patients bone marrow transplant expert bone marrow transplantation an effective and safe way HIV patients HIV patients.

The report is online. courtesy of you, the entire Kaiser Daily Health Policy view Report, search the archives, or sign up for email delivery at Kaiser Daily Health Policy Report reprint for imperial network a free service of The. Henry J published. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.Spectranetics Corporation today announced to halted of enrollment in the CELLO study after the enrollment 61 to the envisaged 85 Patient. Based on a review of preliminary data Spectranetics and agreed representative of Food and Drug Administration that the clinical data from this 61 patients using the TURBO – boosters treated product sufficient for submission to the FDA for testing has. Which follow-up data is be gathered in the beginning of the second quarter 2007, and that 510 application is moment expected that tabled with FDA regulation later during the second quarter of 2007. The TURBO – Booster is a deflecting ‘s sheath, the handling of obstructions relieved of superficial femoral artery the be is the main artery above knee, and is using to group consisting TURBO Spectranetics ‘ Elite laser catheters The CELLOSAITEN study.

Safe Harbor StatementThis press release as defined in-looking statements within the meaning of Section 27A of Securities Exchange Act of 1933 and Section 21E the Securities Exchange Act of 1934. Of coverage, forward-looking statements based on current assumptions which involve risks and uncertainties may cause actual results and outcomes differ materially are based. On these risks and uncertainties include increasing price and product competition, more pressure on costs levels from expanded marketing and clinical efforts, uncertainly success of the enterprise ‘s strategic orientation , dependence on development of new products , intellectual property claims of third parties availability of inventory made vendor, the receiving the FDA approval for new products or applications and the timeliness all approvals the market, the potential size on market opportunity from new products, market acceptance of new products and applications, product defects, price volatility due of the initiation or setting of coverage, or amendments at reviews connected that.